Teva's Pivot to Growth Hits Inflection: Pipeline Expansion, Investment Grade, and Raised Guidance
Teva's Q2 2026 earnings call marked a decisive inflection in its multi-year transformation. The company not only delivered strong financial results but also unveiled concrete pipeline advancements and an investment-grade credit rating—confirming that the Pivot to Growth strategy is now producing tangible outcomes across all four pillars.
Innovative Portfolio Accelerates
The quarter underscored the commercial momentum of Teva's innovative portfolio, led by AUSTEDO, AJOVY, and UZEDY. CEO Richard Francis opened with a clear message: “AUSTEDO, AJOVY and UZEDY all delivered strong Q2 performance, and we are raising our full year revenue guidance for these products.” — Richard Francis, Chief Executive Officer · 2026-07-29 AUSTEDO's global revenue grew 40% year-over-year, prompting a $50 million increase at the midpoint to $2.45–$2.6 billion, while AJOVY's U.S. revenue surged 83%, and UZEDY's momentum continued with 63% TRx growth. This strength is not just about one quarter; it reflects a durable commercial engine capable of generating >$3 billion in peak sales for AUSTEDO alone.
Pipeline Expansion: From Promise to Execution
Perhaps more transformative was the pipeline update. Eric Hughes, Head of R&D, announced two new indications for duvakitug—hidradenitis suppurativa (HS) and fibrostenotic Crohn's disease—unlocking previously untapped non-T2 and fibrotic therapeutic buckets. He stated: “Today, we are very proud to announce the fact that we're adding 2 new indications into our research that includes hydrogeni superativa, which will unlock that non-T2-based indication group and fibrosin Crohn's disease, which unlocks the fibrotic bucket of indications.” — Eric Hughes, Head of Global R&D and Chief Medical Officer · 2026-07-29 This builds on prior quarters where management promised further pipeline expansion; in the April 2026 call, Eric Hughes had said, “We'll be announcing those before the end of the year.” — Eric Hughes, Head of R&D and Chief Medical Officer · 2026-04-29 Now, the science is moving at speed, with a Phase IIb HS study expected and a clear regulatory path for fibrostenotic Crohn's—an area with no approved therapies.
Teva also reaffirmed its biosimilars momentum—now 15 products in the market and 14 in the pipeline—which Richard Francis called a key growth platform: “biosimilars are becoming a growth platform within generics. We now have 15 products in the market and 14 in our pipeline.” — Richard Francis, Chief Executive Officer · 2026-07-29 The company is on track to exceed its $800 million biosimilar revenue target by 2027, supported by strong U.S. execution and European launches.
Financial Transformation
The financial profile is steadily improving. CFO Eli Kalif highlighted the Fitch upgrade: “including the recent upgrade to investment grade by Fitch.” — Eliyahu Kalif, Chief Financial Officer · 2026-07-29 Free cash flow rose 31% to $622 million, gross margins expanded 80 basis points, and net debt-to-EBITDA fell to 2.8x (2.3x excluding the one-time Amylyx impact). The company raised its full-year revenue guidance by $75 million at the midpoint, even as it absorbs the impact of generic REVLIMID—a loss of roughly $1.1 billion in revenue and $700 million in EBITDA. This resilience underscores the structural shift toward higher-margin innovative products.
We continue our growth journey. The themes are very clear. In a critical year for Teva, we delivered exactly what we said we were going to do.
Looking ahead, Teva is now positioned to launch one new product per year for the next five years, including olanzapine LAI this quarter and ecopipam (for Tourette syndrome) in 2027. The new indications for Duvaqetob and the gluten challenge data from the celiac program are additional catalysts. With an investment-grade balance sheet and a disciplined capital allocation framework, Teva is transitioning from a generics powerhouse to a leading biopharma—a story few other companies can match today.